Gujarat Kidney And Super Speciality Appoints Secretarial and Internal Auditors for FY26; Reports Q2 Results
Gujarat Kidney And Super Speciality Limited appointed Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY26. The company reported standalone Q2 FY26 revenue of ₹964.26 lacs and profit after tax of ₹230.12 lacs. Consolidated Q2 FY26 revenue was ₹1,144.99 lacs with profit after tax of ₹389.98 lacs.
The appointment of auditors is a standard corporate governance practice. The financial results provide an update on the company's performance, which is material information for investors. The impact is considered medium as it's a routine disclosure of financial performance and standard appointments.
The announcement includes routine appointments of auditors and the disclosure of financial results. While the financial results are presented, there are no significant positive or negative indicators that would strongly sway the sentiment.
Gujarat Kidney And Super Speciality Limited announced the outcome of its Board Meeting held on March 19, 2026. The Board approved the appointment of Mr. Dharmendra Bhaliya as the Secretarial Auditor and Mr. Siddharth Atulbhai Shah as the Internal Auditor for the Financial Year 2025-26.
The company also disclosed its unaudited standalone and consolidated financial results for the second quarter and six months ended September 30, 2025. For the quarter ended September 30, 2025, standalone revenue from operations was ₹964.26 lacs, with a profit after tax of ₹230.12 lacs. Consolidated revenue from operations for the same period stood at ₹1,144.99 lacs, with a profit after tax of ₹389.98 lacs.
For the half-year ended September 30, 2025, standalone revenue from operations was ₹2,109.25 lacs, with a profit after tax of ₹620.10 lacs. Consolidated revenue from operations for the half-year was ₹2,110.91 lacs, with a profit after tax of ₹623.25 lacs. The company's financial statements were prepared in accordance with Indian Accounting Standards (Ind AS) and reviewed by Y. M. Shah & Co.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under other results related. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.